ETHNOPHARMACOLOGICAL RELEVANCE:Arundo donax Linn is a well-known herbal remedy in traditional healing systems that is commonly indicated for fever, toothache, and dysuria, as documented in the Chinese medicinal literature. Gramine (GRA) is an alkaloid derived from the rhizome of Arundo donax, and studies have confirmed its antiviral, antibacterial, anti-inflammatory, and anticancer properties. However, its specific pharmacological mechanism in the context of ulcerative colitis (UC) has yet to be systematically elucidated.
AIM OF THIS STUDY:The objective of this study was to elucidate the protective role and mechanisms of GRA in UC.
MATERIALS AND METHODS:Network pharmacology and bioinformatics analyses were performed to identify potential targets associated with UC, ferroptosis, and GRA. The direct binding of GRA to COX-2 was confirmed using surface plasmon resonance (SPR), molecular docking, and molecular dynamics (MD) simulations. An in vivo model of UC was established in mice via the administration of 3% dextran sulfate sodium (DSS). In this UC model system, we evaluated the effects of GRA and celecoxib (CEL) alone and in combination. Histopathological changes, intestinal epithelial barrier function, and the levels of ferroptosis-related markers were assessed. Additionally, the combined effects of GRA and CEL on ferroptosis and intestinal barrier integrity were further evaluated in a lipopolysaccharide (LPS)-stimulated NCM460 cell model of colitis.
RESULTS:The network pharmacology analysis identified COX-2 as a core target connecting ferroptosis, UC, and GRA. Direct binding between GRA and COX-2 was subsequently confirmed using molecular docking, MD simulations, and SPR. In vivo, GRA treatment significantly reduced the disease activity index (DAI), histological damage, and cell death in mice with colitis. Further investigation revealed the induction of ferroptosis in mice with colitis, as evidenced by iron overload, glutathione (GSH) depletion, increased reactive oxygen species (ROS) and malondialdehyde (MDA) levels, and upregulated of COX-2 expression. Treatment with GRA, CEL, or their combination significantly ameliorated these ferroptosis-related alterations. Transmission electron microscopy further revealed that GRA counteracted intestinal barrier disruption. Consistently, in vitro experiments demonstrated that all three treatments: GRA, CEL, and GRA + CEL, effectively inhibited ferroptosis and preserved intestinal barrier integrity, thereby mitigating UC pathology. Notably, the results of both in vitro and in vivo experiments indicated that the combination therapy of GRA and CEL (GRA + CEL) exhibited superior efficacy compared with either GRA or CEL treatment alone.
CONCLUSIONS:Our study demonstrated that GRA alleviates UC by protecting the intestinal barrier; notably, GRA + CEL treatment exerted greater therapeutic effects than GRA or CEL alone. The potential underlying mechanism may involve the mitigation of ferroptosis by GRA through the inhibition of COX-2.